AbbVie anti-wrinkle therapy rejected at FDA (ABBV:NYSE)

AbbVie’s anti-wrinkle therapy, TrenibotE (trenibotulinumtoxinE), developed by its Allergan Aesthetics unit, has been rejected by the U.S. Food and Drug Administration (FDA). The company announced on Thursday that the FDA issued a complete response letter regarding the therapy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin